Evidence map›Paper›PMID 25320545›Full record

SynthesisWorld journal of gastroenterology2014

Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis.

Xing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai

Open access · hybridAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Bone Marrow-Derived Stem Cells for Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease.Advances in experimental medicine and biology · 2022
    Article
  10. Review
  11. [Advances in the study of mesenchymal stem cells for end-stage liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Locoregional delivery of stem cell-based therapies.Science translational medicine · 2020
    Review
  17. Liver regeneration and alcoholic liver disease.Annals of translational medicine · 2020
    Review
  18. Article
  19. Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report.JGH open : an open access journal of gastroenterology and hepatology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xing-Nan PanXing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai, Clinical Liver Center, 180 Hospital of People's Liberation Army, Quanzhou 362000, Fujian Province, China.
Lian-Qiu ZhengXing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai, Clinical Liver Center, 180 Hospital of People's Liberation Army, Quanzhou 362000, Fujian Province, China.
Xiao-Huan LaiXing-Nan Pan, Lian-Qiu Zheng, Xiao-Huan Lai, Clinical Liver Center, 180 Hospital of People's Liberation Army, Quanzhou 362000, Fujian Province, China.
The 180th Hospital of PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the efficacy and safety of bone marrow-derived mesenchymal stem cell (BM-MSC) in the treatment of decompensated liver cirrhosis.

methodsThe search terms "bone marrow stem cell" "chronic liver disease" "transfusion" and "injection" were used in the Cochrane Library, Med-Line (Pub-Med) and Embase without any limitations with respect to publication date or language. Journals were also hand-searched and experts in the field were contacted. The studies which used BM-MSC in the treatment of any chronic liver disease were included. Comprehensive Review Manager and Meta-Analyst software were used for statistical analysis. Publication bias was evaluated using Begg's test.

resultsOut of 78 studies identified, five studies were included in the final analysis. The studies were conducted in China, Iran, Egypt and Brazil. Analysis of pooled data of two controlled studies by Review Manager showed that the mean decline in scores for the model for end-stage liver disease (MELD) was -1.23 [95%CI: -2.45-(-0.01)], -1.87 [95%CI: -3.16-(-0.58)], -2.01 [95%CI: -3.35-(-0.68)] at 2, 4 and 24 wk, respectively after transfusion. Meta-analysis of the 5 studies showed that the mean improvement in albumin levels was -0.28, 2.60, 5.28, 4.39 g/L at the end of 8, 16, 24, and 48 wk, respectively, after transfusion. MELD scores, alanine aminotransferase, total bilirubin levels and prothrombin times improved to some extent. BM-MSC injections resulted in no serious adverse events or complications.

conclusionBM-MSC infusion in the treatment of decompensated liver cirrhosis improved liver function. At the end of year 1, there were no serious side effects or complications.

Indexed as

Bone Marrow TransplantationMesenchymal Stem Cell TransplantationChi-Square DistributionEnd Stage Liver DiseaseHumansLiver CirrhosisLiver Function TestsOdds RatioPredictive Value of TestsRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeBone marrow stem cellDecompensated liver cirrhosisMeta-analysisTransfusion

Identifiers

PMID25320545
PMCPMC4194591
OpenAlexW2089432538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.